Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Rao Prabhala.
Connection Strength

1.075
  1. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2021 Jul 21.
    View in: PubMed
    Score: 0.244
  2. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
    View in: PubMed
    Score: 0.239
  3. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
    View in: PubMed
    Score: 0.112
  4. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4.
    View in: PubMed
    Score: 0.081
  5. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
    View in: PubMed
    Score: 0.059
  6. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
    View in: PubMed
    Score: 0.045
  7. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
    View in: PubMed
    Score: 0.034
  8. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
    View in: PubMed
    Score: 0.032
  9. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
    View in: PubMed
    Score: 0.031
  10. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34.
    View in: PubMed
    Score: 0.027
  11. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
    View in: PubMed
    Score: 0.027
  12. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84.
    View in: PubMed
    Score: 0.026
  13. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
    View in: PubMed
    Score: 0.026
  14. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.
    View in: PubMed
    Score: 0.025
  15. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
    View in: PubMed
    Score: 0.024
  16. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7.
    View in: PubMed
    Score: 0.023
  17. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.